Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantation

Transplantation Proceedings

Volumn 43, Issue 9, 2011, Pages 3367-3376

  Gamboa, O ^a,g   Montero, C ^b   Mesa, L ^c   Benavides, C ^d   Reino, A ^e   Torres, R E ^f   Castillo, J S ^g  

^a Fundación Esensa   (Colombia)

^b Division of Gastroenterology   (Colombia)

^c FUNDACIÓN VALLE DEL LILI   (Colombia)

^d FUNDACIÓN CARDIOINFANTIL INSTITUTO DE CARDIOLOGÍA   (Colombia)

^e Hospital Universitario San Vicente de Paul   (Colombia)

^f HOSPITAL DE SAN JOSÉ   (Colombia)

^g Instituto Para la Evaluación de la Calidad y Atención en Salud IECAS   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ALBUMINURIA; BLOOD PRESSURE; COLOMBIA; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFORMATION RETRIEVAL; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MEDICAL HISTORY; PRIORITY JOURNAL; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; COLOMBIA; COST-BENEFIT ANALYSIS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MARKOV CHAINS; REGISTRIES; RENAL INSUFFICIENCY; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 81455132447     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.09.092     Document Type: Conference Paper

References (42)

1. A. Grassmann, S. Gioberge, and Moeller End-stage renal disease: global demographics in 2005 and observed trends Artif Organs 30 2006 895
2. A. Cusumano, G.G. Garcia, and B.C. Gonzalez The Latin American Dialysis and Transplant Registry: report 2006 Ethnicity Dis 19 1 Suppl 1 2009 S1 S3
3. R.A. Gomez Renal disease in Colombia Ren Fail 28 2006 643
4. R. Oberbauer Protocol conversion from a calcineurin inhibitor based therapy to sirolimus Transplantation 87 8 Suppl 2009 S7
5. System USRD USRDS 2007 annual data report 2007 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
6. S. Hariharan, M.A. McBride, and W.S. Cherikh Post-transplant renal function in the first year predicts long-term kidney transplant survival Kidney Int 62 2002 311
7. K.C. Mange, B. Cizman, and M. Joffe Arterial hypertension and renal allograft survival JAMA 283 2000 633
8. S.M. Flechner, J. Kobashigawa, and G. Klintmalm Calcineurin inhibitorsparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity Clin Transplant 22 2008 1
9. S.M. Flechner, D. Goldfarb, and C. Modlin Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine Transplantation 74 2002 1070
10. R. Oberbauer, H. Kreis, and R.W. Johnson Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study Transplantation 76 2003 364
11. A.V. Mulay, N. Hussain, and D. Fergusson Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials Am J Transplant 5 2005 1748
12. R.K. Wali, and M.R. Weir Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? Curr Opin Organ Transplant 13 2008 614
13. A. Lundh, and P.C. Gotzsche Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies BMC Med Res Methodol 8 2008 22
14. D.K. Miller, and S.M. Homan Determining transition probabilities: confusion and suggestions Med Decis Making 14 1994 52
15. J.M. Grinyo, J.M. Campistol, and J. Paul Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation Am J Transplant 4 2004 1308
16. C.J. Watson, J. Firth, and P.F. Williams A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation Am J Transplant 5 2005 2496
17. J.M. Morales, J.M. Grinyo, and J.M. Campistol Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus Transplantation 86 2008 620
18. F.P. Schena, M.D. Pascoe, and J. Alberu Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial Transplantation 87 2009 233
19. T.C. Perason, S. M, A. Patel, and J. Scandling Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the Spare-the-Nephron (STN) trial [abstract no. 129] American Transplant Congress Toronto, Canada May 31June 4, 2008
20. S.M.G.M. Flechner, S. Steinberg, J.B. Copley ORION Trial Investigators The efficacy of sirolimus (SRL) and tacrolimus (TAC) withdrawal versus SRL and mycophenolate mofetil (MMF) compared with TAC and MMF in de novo renal allograft recipients: Interim results from the Orion study [abstract] J Am Soc Nephrol 18 2007 95A
21. WHO Commission on Macroeconomics and Health Macroeconomics and health: investing in health for economic development Report of the Commission on Macroeconomics and Health: Executive Summary 2001 World Health Organization Geneva
22. J.S. Jurgensen, W. Arns, and B. Hass Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach Eur J Health Econ 11 2010 15
23. S.R. Earnshaw, C.N. Graham, and W.D. Irish Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation J Am Soc Nephrol 19 2008 1807
24. P. McEwan, K. Baboolal, and P. Conway Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom Clin Ther 27 2005 1834
25. P. McEwan, S. Dixon, and K. Baboolal Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK Pharmacoeconomics 24 2006 67
26. A.C. Webster, V.W. Lee, and J.R. Chapman Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients Cochrane Database Syst Rev 2 2006 CD004290
27. R.A. Wolfe, V.B. Ashby, and E.L. Milford Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant N Engl J Med 341 1999 1725
28. H.M. Kauffman Malignancies in organ transplant recipients J Surg Oncol 94 2006 431
29. M. Silva Jr, A.R. Marra, and C.A. Pereira Bloodstream infection after kidney transplantation: epidemiology, microbiology, associated risk factors, and outcome Transplantation 90 2010 581
30. A.M. Cueto-Manzano, E. Rojas, and G. Rosales Risk factors for long-term graft loss in kidney transplantation: experience of a Mexican single-center Rev Invest Clin 54 2002 492
31. M. Arnol, J.C. Prather, and A. Mittalhenkle Long-term kidney regraft survival from deceased donors: risk factors and outcomes in a single center Transplantation 86 2008 1084
32. B.L. Kasiske, J.J. Snyder, and D. Gilbertson Diabetes mellitus after kidney transplantation in the United States Am J Transplant 3 2003 178
33. R.J. Knight, L. Burrows, and C. Bodian The influence of acute rejection on long-term renal allograft survival: a comparison of living and cadaveric donor transplantation Transplantation 72 2001 69
34. D. Mikhalski, K.M. Wissing, and L. Ghisdal Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression Transplantation 85 7 Suppl 2008 S3
35. S. Pita-Fernandez, F. Valdes-Canedo, and T. Seoane-Pillado Influence of early graft function after renal transplantation and its impact on long-term graft and patient survival Transplant Proc 42 2010 2856
36. I. Quiroga, P. McShane, and D.D. Koo Major effects of delayed graft function and cold ischaemia time on renal allograft survival Nephrol Dial Transplant 21 2006 1689
37. K.S. Reddy, D. Davies, and D. Ormond Impact of acute rejection episodes on long-term graft survival following simultaneous kidney-pancreas transplantation Am J Transplant 3 2003 439
38. C. Maffei, S. Sandrini, and A. Galanopoulou Patient mortality after graft failure reduces kidney transplant patient survival only in the long term: an "intention to treat" analysis Transplant Proc 40 2008 1862
39. J.C. González, J.H. Walker, and T.R. Einarson Cost-of-illness study of type 2 diabetes mellitus in Colombia Rev Panam Salud Pub 26 2009 55
40. N. Pérez, R. Murillo, and C. Pinzón Costos de la atención médica del cáncer de pulmón, la EPOC y el IAM atribuibles al consumo de tabaco en Colombia (proyecto multicéntrico de la OPS) Rev Colomb Cancerol 11 2007 241
41. O. Gamboa, S. Díaz, L. Chicaíza, and M. García Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cáncer Biomedica 30 2010 46
42. O.A. Gamboa, L. Chicaíza, and M. García Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia Salud Pub Mex 50 2008 276